Filing Flows › Gyre Therapeutics (GYRE) › Q2 2026
Gyre Therapeutics (GYRE) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
Gyre Therapeutics (GYRE) reported revenue of $29.1M for the second quarter 2026 (Q2 2026), -2% from a year earlier and +29% from the quarter before. Operating margin was -49.3%, net loss $23.0M (79.0% of revenue).
Gyre Therapeutics, Q2 2026: revenue $29.1M (-2% year over year), operating margin -49.3%, net loss $23.0M, operating cash flow −$16.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29.1M | +29% | -2% |
| Operating profit | −$14.4M | — | -762% |
| Net earnings | −$23.0M | — | -1559% |
| Operating cash flow | −$16.7M | -626% | -901% |
What changed
Revenue was $29.1M in Q2 2026, down 2% year over year and up 29% from the previous quarter. Gyre Pharmaceuticals was the largest line at 100% of revenue. Gyre lost $3.0M year over year (down 100%), 470% of the total change.
Operating costs exceeded revenue by $14.4M, an operating margin of -49.3%. The fastest-growing cost line was Other operating costs (+173%). The quarter ended with a net loss of $23.0M, wider than the previous quarter's $9.9M loss. Minority interests bore $8.7M of it: to shareholders the quarter was a loss of $14.3M.
Operating cash flow was −$16.7M. Non-cash charges added back $1.5M of depreciation and amortization and $2.1M of share-based compensation. Working capital and other items added $2.7M. Capital expenditures of $262K exceeded it, leaving free cash flow of −$17.0M.
Questions
What was Gyre Therapeutics' revenue in the second quarter 2026?
Gyre Therapeutics (GYRE) reported revenue of $29.1M for the second quarter 2026 (Q2 2026), -2% from a year earlier and +29% from the quarter before.
Was Gyre Therapeutics profitable in the second quarter 2026?
Operating loss was $14.4M (-49.3% of revenue) and net loss $23.0M.
Source: Gyre Therapeutics 10-Q on SEC EDGAR.